Effect of L-Glutamine on Pulmonary Artery Pressure in Patients With Non-Transfusion-Dependent Thalassemia
Status:
COMPLETED
Trial end date:
2025-09-27
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn whether L-glutamine can help lower pulmonary artery pressure in adults with non-transfusion-dependent thalassemia (NTDT).
The main questions it aims to answer are:
Does L-glutamine reduce pulmonary artery pressure after 60 days of treatment?
Is the effect of L-glutamine different from standard care alone?
Researchers will compare two groups:
Intervention group: Participants receive oral L-glutamine in addition to their standard treatment.
Control group: Participants continue with standard treatment only.
Participants will:
Take either L-glutamine (by mouth) or standard care for 60 days. Undergo echocardiography at the beginning and end of the study to measure pulmonary artery pressure.
Attend follow-up visits to monitor safety, adherence, and possible side effects.